Immunotherapy With Nivolumab in Combination With Lenvatinib for Advanced Stage Hepatocellular Carcinoma
Status:
Recruiting
Trial end date:
2022-05-01
Target enrollment:
Participant gender:
Summary
This is an exploratory, open-label, single arm, multicenter phase II trial for the evaluation
of efficacy and feasibility (as determined by safety and tolerability) of immunotherapy with
nivolumab in combination with lenvatinib for patients with multinodular, advanced stage
hepatocellular carcinoma in first line therapy
Phase:
Phase 2
Details
Lead Sponsor:
IKF Klinische Krebsforschung GmbH at Krankenhaus Nordwest Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest